Sep 9, 2026 earnings call — Strategic review ends; CooperVision inventory actions
Cooper reported record quarterly free cash flow of $273 million, and ended a strategic review while CooperVision cut U.S. channel inventory.
Revenue $1.1B (est $1.1B) · EPS $1.15 (est $1.12) · Next-quarter revenue outlook $1.1B–$1.1B
Key quotes
"At CooperVision, however, we proactively reduced U.S. channel inventory that weighed on our results and will continue to impact Q4."
"Ultimately, however, the Board unanimously determined that shareholders are better served by continued ownership than by pursuing a transaction at this time."
"Supported by this strong cash generation, we repurchased $339 million of shares during the quarter, bringing fiscal year-to-date repurchases to $445 million while maintaining leverage below 2x."
Analyst Q&A 12
Revenue cut: destock vs consumption
Q (Jonathan Block): Is the revenue guidance cut all due to channel inventory (destock) or due to weaker end-market consumption? Does the consumption assumption also apply to fiscal Q4?
A: Management said the cut was entirely channel inventory related. They said U.S. consumption stayed mid-single-digits all year and they expect it to remain steady, so the revenue reduction ties only to channel destocking.
"Meaning the entire reason for the reduction in the revenue guidance for CooperVision was tied to just channel inventory." — Albert White (CEO)
Why destocking happened and risk to 2027
Q (Jeffrey Johnson): What caused the destock across product lines? Has the company ring-fenced the issue so it won't extend into early fiscal 2027? Also, has the APAC view changed?
A: They said they have ring-fenced the issue after a deep review and expect the vast majority to be behind them in Q4. Much of the destock was tied to Biofinity, some dailies, and legacy hydrogels; Asia Pac is stabilizing as they finish rationalization.
"A lot of it was tied to Biofinity, but there was other." — Albert White (CEO)
Q3 and Q4 U.S. inventory impact size
Q (Lei Huang): How much did U.S. inventory reduction reduce reported growth in fiscal Q3, and what is the expected impact in fiscal Q4?
A: They said the Americas would have grown about 5% in Q3 without the inventory actions. They expect a similar inventory reduction to occur in Q4 in the U.S., EMEA and Asia Pac.
"The Americas would have reported growth around 5% in Q3 if we hadn't made the inventory reduction moves." — Albert White (CEO)
Q4 margin drivers and buyback
Q (Jason Bednar): Is the implied Q4 operating margin mid-20s reasonable, why is it down, and is there any buyback in the EPS guide?
A: They said there is no buyback assumed in guidance. The margin pressure comes from lost tariff benefit, slightly more negative FX and new investments in CooperSurgical, which started in Q3 and will affect margins this year.
Timing and progress of destocking
Q (Robert Marcus): When did destocking start and where are you now in the process? Was inventory this year above average and how far to go?
A: They said they are about halfway through the destock and completed part in Q3 with the remainder in Q4. They confirmed this year ran above average and cited stocking tied to new private label contracts as a cause.
"We did it here in Q3, and we're going to do the other half of it in Q4." — Albert White (CEO)
Why growth lagged and salesforce shortage
Q (Joanne Wuensch): With contact lens market growing, can CooperVision grow with the market next year? What is causing execution gaps?
A: They said the problem is commercial execution at the final step, not product or contracts. They acknowledged they don't have enough salespeople in the field versus competitors and are now investing to add the salesforce and marketing to fix execution.
"We don't have enough salespeople out there. Like, hindsight 20/20, we should have moved faster on this." — Albert White (CEO)
Why keep CooperSurgical (CSI) with CooperVision
Q (Steven Lichtman): After the strategic review, why are the two businesses stronger together despite limited synergies? How will free cash be used going forward?
A: They pointed to P&L strength from shared services, operating leverage and strong cash flow as the reason to keep both businesses together. The company will focus heavily on CooperVision organic growth with cash deployment prioritized to that business.
"100%, yes. The very heavy focus right now on CooperVision organic growth." — Albert White (CEO)
Where to add sales reps and pricing outlook
Q (David Saxon): Which regions need more sales reps to hit mid-single digit growth, and what is the pricing environment?
A: They said U.S. is the priority and the sales expansion will add coverage for about 5,000 additional doors; Europe and Asia Pac also have targeted hires. On pricing, higher-priced products are performing better and there remains potential to take price given inflation.
"The addition of this direct sales force and the expansion that we're doing right now is going to add coverage for something like 5,000 additional doors." — Albert White (CEO)
CSI strategic review insights and fertility investment
Q (Navann Ty Dietschi): What insights came from the CSI strategic review and what investments to drive fertility growth started in the quarter? Is the fertility settlement fully resolved?
A: They said the review drilled into profitability by product and geography and identified ways to improve CooperSurgical's profitability. They are investing in fertility R&D and genomics launches, and they confirmed the fertility settlement is fully settled with no new issues.
"That is fully settled. So there's nothing new on that." — Albert White (CEO)
Competitive dynamics and product gaps
Q (Bradley Bowers): Are competitive dynamics in your favor and where are you missing exposure (e.g., super premium lenses)?
A: They said competitive position remains favorable but they lack presence in the super premium daily segment, which has higher revenue per patient. They noted launches like MyDay Energys target that premium space and they expect to gain ground there.
"I will say that the area where losing share is the wrong word, but where we don't operate is kind of in the super premium segment." — Albert White (CEO)
Product portfolio and R&D timing
Q (Brett Fishbin): Are portfolio or R&D changes coming to address the premium gap and how active is the pipeline?
A: They said the portfolio is strong but commercial support was lacking, so they are adding sales and marketing. They have accelerated R&D, pulling some launches forward by a couple years and focusing on a narrower set of high-impact new products.
"I will say with respect to R&D and new products, we have accelerated that activity." — Albert White (CEO)
China and Asia Pacific strategy
Q (Issie Kirby): China has been a drag—how big is the market and will you stay? What happened with MiSight in China?
A: They said China was a struggle this quarter and MiSight has not gained traction there; they are reengineering the team and exploring channels like e-commerce. China business is now relatively small—'less than 2% of revenues this quarter on a consolidated basis'—and they are taking a hard look at how to reinvigorate it.
"I mean, I think it's less than 2%. It is less than 2% of revenues this quarter on a consolidated basis." — Albert White (CEO)